Fairfield Financial Advisors, LTD Editas Medicine, Inc. Transaction History

Fairfield Financial Advisors, LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$4.67 - $7.28 $490 - $764	105 New	105 $490,000
Q4 2023 Nov 04, 2024	BUY	$6.25 - $11.11 $1,875 - $3,333	300 Added 55.05%	845 $8.56 Million
Q2 2023 Nov 04, 2024	BUY	$6.36 - $11.47 $3,466 - $6,251	545 New	545 $4.49 Million
Q1 2023 Nov 04, 2024	BUY	$7.03 - $11.53 $3,831 - $6,283	545 New	545 $3.83 Million
Q3 2022 Oct 07, 2024	BUY	$12.16 - $19.42 $5,350 - $8,544	440 Added 419.05%	545 $6.67 Million
Q2 2022 Oct 07, 2024	BUY	$9.99 - $21.35 $4,395 - $9,394	440 Added 419.05%	545 $6.45 Million
Q1 2022 Oct 07, 2024	BUY	$14.08 - $27.63 $6,195 - $12,157	440 Added 419.05%	545 $10.4 Million

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $83.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Fairfield Financial Advisors, LTD, based on Form 13F filings with the SEC.

Stay updated on Fairfield Financial Advisors, LTD with notifications on news.